Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

MD Anderson, Takeda partner for CAR NK cell therapies
The University of Texas MD Anderson Cancer Center partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to develop and commercialize up to four allogeneic CAR NK cell therapies, including CD19 and BCMA-targeted therapies engineered to express IL-15 for enhanced proliferation and

Read the full 490 word article

How to gain access

Continue reading with a
two-week free trial.